Pfizer Exubera Has Mid-Year Launch Trigger, Heavy Dose Of Instructions
Executive Summary
Marketing of Pfizer's inhaled insulin Exubera for treatment of adult diabetes mellitus is expected to begin by the end of August
You may also be interested in...
Abbott Expands Pharmaceutical Pipeline With $3.7 Bil Kos Acquisition
Abbott's proposed $3.7 bil. acquisition of Kos Pharmaceuticals will help diversify Abbott's existing cardiovascular franchise, and could also expand its pipeline into respiratory diseases
Abbott Expands Pharmaceutical Pipeline With $3.7 Bil Kos Acquisition
Abbott's proposed $3.7 bil. acquisition of Kos Pharmaceuticals will help diversify Abbott's existing cardiovascular franchise, and could also expand its pipeline into respiratory diseases
Exubera Reimbursement Plan May Focus On Outcomes Relative To Oral Agents
Pfizer's strategy for securing reimbursement for Exubera could focus on the inhaled insulin's benefits on overall healthcare outcomes relative to oral diabetes therapies